News & Events category:
Wythenshawe, Trafford, Withington and Altrincham

Cellular (T-cell) immunity against SARS-CoV-2 is likely to be present within most adults for at least six months after infection, according to research carried out at MFT.

A lung cancer patient at Wythenshawe Hospital has taken part in a national project led by Manchester researchers, investigating changes in radiotherapy treatments during COVID-19.

The first UK patient has been treated in new COVID-19 research trialling the impact of an experimental arthritis drug, otilimab, on severe lung disease related to COVID-19.

Manchester University NHS Foundation Trust’s (MFT) ground-breaking qUEST research, part of the Manchester Lung Health Checks programme, has been named among the top-recruiting cancer studies in Englan

Manchester doctors have played a leading role in global coronavirus research, which has found the first drug shown to increase survival rates in people hospitalised with COVID-19.

A Wythenshawe Hospital patient with COVID-19 is the first Manchester University NHS Foundation Trust recruit to a clinical trial investigating the drug Anakinra to treat COVID-19.

Many MFT staff members are involving their children in our vitally important COVID-19 research, with some of them sharing their experiences.